Reuben Ruby Shamir

Reuben Ruby Shamir

Auto-generated profile, based on publicly available information

Reuben Ruby Shamir

KI Research Institute, Kfar Malal, Israel

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TVTali Voloshin
Tali Voloshin
RSRosa Shnaiderman
Rosa Shnaiderman
AVAlexandra Volodin
Alexandra Volodin
RSReuben Ruby Shamir
Reuben Ruby Shamir
NKNoa Kaynan
Noa Kaynan
YPYoram Palti
Yoram Palti
Tumor Treating Fields (TTFields) are noninvasive, alternating electric fields within the intermediate frequency range (100–300 kHz) that are utilized as an antimitotic cancer treatment. TTFields are loco-regionally delivered to the tumor region through 2 pairs of transducer arrays placed on the skin. This novel treatment modality has been FDA-approved for use in patients with glioblastoma and malignant pleural mesothelioma based on clinical trial data demonstrating efficacy and safety; and is currently under investigation in other types of solid tumors. TTFields were shown to induce an anti-mitotic effect by exerting bi-directional forces on highly polar intracellular elements, such as tubulin and septin molecules, eliciting abnormal microtubule polymerization during spindle formation as well as aberrant cleavage furrow formation. Previous studies have demonstrated that TTFields inhibit metastatic properties in cancer cells. However, the consequences of TTFields application on cytoskeleton dynamics remain undetermined. In this study, methods utilized in combination to study the effects of TTFields on cancer cell motility through regulation of microtubule and actin dynamics included confocal microscopy, computational tools, and biochemical analyses. Mechanisms by which TTFields treatment disrupted cellular polarity were (1) interference with microtubule assembly and directionality; (2) altered regulation of Guanine nucleotide exchange factor-H1 (GEF-H1), Ras homolog family member A (RhoA), and Rho-associated coiled-coil kinase (ROCK) activity; and (3) induced formation of radial protrusions of peripheral actin filaments and focal adhesions. Overall, these data identified discrete effects of TTFields that disrupt processes crucial for cancer cell motility.

20 November 2014 in International Journal of Computer Assisted Radiology and Surgery
Verified
Journal Article
Closed access
PDF file
MTM. Trope
M. Trope
RSR. R. Shamir
R. R. Shamir
LJLeo Joskowicz
Leo Joskowicz
ZMZ. Medress
Z. Medress
GRG. Rosenthal
G. Rosenthal
YSY. Shoshan
Y. Shoshan

4 March 2010
Verified
Conference Paper
Closed access
PDF file
RSReuben R. Shamir
Reuben R. Shamir
LJLeo Joskowicz
Leo Joskowicz
LALuca Antiga
Luca Antiga
RFRoberto I. Foroni
Roberto I. Foroni
YSYigal Shoshan
Yigal Shoshan
We present a new preoperative planning method to quantify and help reduce the risk associated with needle and tool insertion trajectories in image-guided keyhole neurosurgery. The goal is to quantify the risk of a proposed straight trajectory, and/or to find the trajectory with the lowest risk to nearby brain structures based on pre-operative CT/MRI images. The method automatically computes the risk associated with a given trajectory, or finds the trajectory with the lowest risk to nearby brain structures based on preoperative image segmentation and on a risk volume map. The surgeon can revise the suggested trajectory, add a new one using interactive 3D visualization, and obtain a quantitative risk measure. The trajectory risk is evaluated based on the tool placement uncertainty, on the proximity of critical brain structures, and on a predefined table of quantitative geometric risk measures. Our preliminary results on a clinical dataset with eight targets show a significant reduction in trajectory risk and a shortening of the preoperative planning time as compared to the conventional method.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
HAHadas Ben Atya
Hadas Ben Atya
OPOren Peles
Oren Peles
RSReuben Shamir
Reuben Shamir
ZBZeev Bomzon
Zeev Bomzon
Introduction: Tumor Treating Fields (TTFields) is a treatment modality for glioblastoma multiforme (GBM) and other malignant tumors, utilizing low-intensity, intermediate frequency (100-300kHz) alternating electric field delivered through noninvasive transducer arrays. TTFields are currently being tested in a phase III clinical trial for the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Previous studies have demonstrated that the treatment efficacy increases when the dose of TTFields delivered to the tumor is at least 1 V/cm. Thus, personalized simulations to estimate the dose are performed as part of the patient treatment planning. For NSCLC treatment, these simulations require the segmentation of torso tissues. We are currently developing a semi-automatic software for the segmentation of these tissues. Achieving highly accurate segmentation is time consuming and not always necessary. Therefore, in this study we assess the level of segmentation accuracy that is required for TTFields dose estimation. Methods: We introduce a novel pipeline for evaluating the sensitivity of TTFields treatment planning errors in the segmentation of torso tissues. To this end, we incorporated an expert-segmented torso volume and artificially placed NSCLC tumors of different sizes in the vicinity of the tested torso tissue. We employed relaxations to the segmentation algorithm and derived the TTFields distribution with and without the simulated segmentation errors. We then computed the treatment planning error as the per-voxel average deviation of the TTFields dose computed over the erroneous segmentation from the reference one. The dose was calculated over the simulated tumor location and over the entire lung volume. Results: We have evaluated our sensitivity analysis pipeline on 9 different test cases. Based on previous analysis, we have set our tolerable target error to be 0.1 V/cm. Our results show that 6 out of the 9 tests were within the target, whereas the other 3 exceeded the target, requiring algorithmic refinements. Conclusions: We have presented a method for estimating the sensitivity of lung cancer TTFields treatment planning to segmentation errors. This method is used to evaluate the required accuracy of the semi-automatic torso segmentation tool that we are currently developing. Our method can be further extended to other types of tumors in different regions of the body. Citation Format: Hadas Ben Atya, Oren Peles, Reuben Shamir, Zeev Bomzon. Lung cancer TTFields treatment planning sensitivity to errors in torso segmentation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3070.

23 September 2020
Verified
Book Chapter
Closed access
PDF file
RSReuben R. Shamir
Reuben R. Shamir
ZBZeev Bomzon
Zeev Bomzon

6 October 2020 in arXiv
Verified
Preprint
Open access
PDF file
RSReuben R Shamir
Reuben R Shamir
ZBZeev Bomzon
Zeev Bomzon
Tumor Treating Fields (TTFields) is an FDA approved treatment for specific types of cancer and significantly extends patients life. The intensity of the TTFields within the tumor was associated with the treatment outcomes: the larger the intensity the longer the patients are likely to survive. Therefore, it was suggested to optimize TTFields transducer array location such that their intensity is maximized. Such optimization requires multiple computations of TTFields in a simulation framework. However, these computations are typically performed using finite element methods or similar approaches that are time consuming. Therefore, only a limited number of transducer array locations can be examined in practice. To overcome this issue, we have developed a method for fast estimation of TTFields intensity. We have designed and implemented a method that inputs a segmentation of the patients head, a table of tissues electrical properties and the location of the transducer array. The method outputs a spatial estimation of the TTFields intensity by incorporating a few relevant parameters in a random-forest regressor. The method was evaluated on 10 patients (20 TA layouts) in a leave-one-out framework. The computation time was 1.5 minutes using the suggested method, and 180-240 minutes using the commercial simulation. The average error was 0.14 V/cm (SD = 0.06 V/cm) in comparison to the result of the commercial simulation. These results suggest that a fast estimation of TTFields based on a few parameters is feasible. The presented method may facilitate treatment optimization and further extend patients life.